Ultomiris drug market expected to grow faster by 2035, driven by expanded indications and the rollout of a subcutaneous formulation

According to an IndexBox report, the market for Ultomiris (ravulizumab-cwvz), a long-acting C5 inhibitor developed by Alexion and AstraZeneca Rare Disease, is projected to expand at a compound annual growth rate of 8.2% from 2026 to 2035, with the market index reaching 220 in 2035 (2025 = 100).